Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 4:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–45 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: glibenclamide Clear all
Completed Phase 4 Interventional Results available

Metabolic Analysis for Treatment Choice in Gestational Diabetes Mellitus

NCT03029702
View directory record Official record
Conditions
Gestational Diabetes, Diabetes, Gestational, Pregnancy in Diabetes
Interventions
Insulin, Glyburide, Metformin
Drug
Lead sponsor
Maisa N. Feghali, MD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 28, 2024 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets Under Fasting Conditions

NCT00865436
View directory record Official record
Conditions
Healthy
Interventions
Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg, CLUCOVANCE® 5 mg/500 mg Tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 16, 2010 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Glyburide and Metformin for Gestational Diabetes Mellitus (GDM)

NCT01329016
View directory record Official record
Conditions
Gestational Diabetes Mellitus
Interventions
Glyburide, Metformin, Glyburide-Metformin combination
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
177 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
4
States / cities
Indianapolis, Indiana • Pittsburgh, Pennsylvania • Galveston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Glyburide Healthy Volunteer Study

NCT01716338
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Glyburide, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 40 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 15, 2014 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Not applicable Interventional

Gestational Diabetes Diagnostic Methods

NCT01540396
View directory record Official record
Conditions
Gestational Diabetes
Interventions
Dietary modification and medications
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Not applicable Interventional Results available

Preferred Treatment of Type 1.5 Diabetes

NCT00194896
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
rosiglitazone, glyburide
Drug
Lead sponsor
University of Washington
Other
Eligibility
35 Years to 69 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Phase 4 Interventional Results available

Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM

NCT01107717
View directory record Official record
Conditions
Diabetes
Interventions
metformin\pioglitazone\exenatide, metformin, glyburide and glargine
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 80 Years
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Sep 23, 2026, 4:32 AM EDT
Terminated Phase 3 Interventional Results available

Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction

NCT02864953
View directory record Official record
Conditions
Brain Edema, Stroke, Acute
Interventions
BIIB093, Placebo
Drug
Lead sponsor
Remedy Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
74
States / cities
Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 59 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2024 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Results available

Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus.

NCT00286468
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Alogliptin and glyburide, Glyburide
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
54
States / cities
Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets Under Non-fasting Conditions

NCT00864734
View directory record Official record
Conditions
Healthy
Interventions
Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg, CLUCOVANCE® 5 mg/500 mg Tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 16, 2010 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Metformin Compared to Glyburide in Gestational Diabetes

NCT00965991
View directory record Official record
Conditions
Gestational Diabetes
Interventions
metformin, Glyburide
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
13 Years and older · Female only
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Phase 3 Interventional

Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide

NCT00279045
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Rosiglitazone, glyburide, metformin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 75 Years
Enrollment
4,426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
178
States / cities
Anniston, Alabama • Birmingham, Alabama • Mesa, Arizona + 132 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Phase 3 Interventional

A Research Study to Determine the Safety and Efficacy of Glucovance Compared to Metformin and Glyburide in Children and Adolescents With Type 2 Diabetes.

NCT00035542
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Glucovance (metformin HCl/glyburide), metformin HCl, glyburide
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
9 Years to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
50
States / cities
Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 43 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Phase 1 Interventional

A Drug-Drug Interaction Study of GK Activator (2) and Glyburide in Patients With Type 2 Diabetes.

NCT00388986
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
GK Activator (2), Glyburide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Cypress, California • Honolulu, Hawaii • Buffalo, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients

NCT01798706
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Lixisenatide (AVE0010), Placebo, Antidiabetic background therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
70 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
14
States / cities
La Jolla, California • Norwalk, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Sep 23, 2026, 4:32 AM EDT
Active, not recruiting No phase listed Observational

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study

NCT05220917
View directory record Official record
Conditions
Cardiovascular Events, Type2 Diabetes, Renal Disease
Interventions
SGLT2 inhibitor, DPP-4 inhibitor, GLP-1RA, 2nd generation SU
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
781,430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 23, 2026, 4:32 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of BIIB093 in Participants With Brain Contusion

NCT03954041
View directory record Official record
Conditions
Brain Contusion
Interventions
BIIB093, Placebo
Drug
Lead sponsor
Remedy Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
25
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Sep 23, 2026, 4:32 AM EDT
Not yet recruiting Phase 1 Interventional

OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis

NCT07221799
View directory record Official record
Conditions
Multiple Sclerosis, Neuropathic Pain
Interventions
glibenclamide, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Sep 23, 2026, 4:32 AM EDT
Not listed No phase listed Observational

Impact of Sulphonylureas on Neurodevelopmental Outcomes in KCNJ11-related Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome

NCT05751525
View directory record Official record
Conditions
Neurodevelopmental Disorders, Intellectual Disability, Development Delay, ADHD, Autism Spectrum Disorder, Epilepsy
Interventions
Sulfonylurea
Drug
Lead sponsor
Royal Devon and Exeter NHS Foundation Trust
Other
Eligibility
2 Years to 50 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Phase 2 Interventional

Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals

NCT01794182
View directory record Official record
Conditions
Ischemic Stroke, Malignant Edema
Interventions
Glyburide for Injection, Placebo
Drug
Lead sponsor
Remedy Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
17
States / cities
Tucson, Arizona • Stanford, California • New Haven, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Not applicable Interventional

A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program

NCT02297126
View directory record Official record
Conditions
Adverse Drug Reaction
Interventions
Pharmacogenetic Intervention Arm (pharmacogenetic testing)
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
4,465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Sep 23, 2026, 4:32 AM EDT